68 related articles for article (PubMed ID: 1394233)
1. Somatostatin receptors in human renal cell carcinomas.
Reubi JC; Kvols L
Cancer Res; 1992 Nov; 52(21):6074-8. PubMed ID: 1394233
[TBL] [Abstract][Full Text] [Related]
2. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.
Reubi JC; Chayvialle JA; Franc B; Cohen R; Calmettes C; Modigliani E
Lab Invest; 1991 Apr; 64(4):567-73. PubMed ID: 1673164
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
Uhlman DL; Nguyen P; Manivel JC; Zhang G; Hagen K; Fraley E; Aeppli D; Niehans GA
Clin Cancer Res; 1995 Aug; 1(8):913-20. PubMed ID: 9816062
[TBL] [Abstract][Full Text] [Related]
6. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
Reubi JC; Schaer JC; Waser B; Mengod G
Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
8. Pax-2 expression in adult renal tumors.
Daniel L; Lechevallier E; Giorgi R; Sichez H; Zattara-Cannoni H; Figarella-Branger D; Coulange C
Hum Pathol; 2001 Mar; 32(3):282-7. PubMed ID: 11274636
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
13. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma.
Lager DJ; Slagel DD; Palechek PL
Mod Pathol; 1994 Jun; 7(5):544-8. PubMed ID: 7937720
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors in differentiated ovarian tumors.
Reubi JC; Horisberger U; Klijn JG; Foekens JA
Am J Pathol; 1991 May; 138(5):1267-72. PubMed ID: 1850962
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
Rodins K; Cheale M; Coleman N; Fox SB
Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
[TBL] [Abstract][Full Text] [Related]
16. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
17. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
18. Calponin h1 expression in renal tumor vessels: correlations with multiple pathological factors of renal cell carcinoma.
Islam AH; Ehara T; Kato H; Hayama M; Kobayashi S; Igawa Y; Nishizawa O
J Urol; 2004 Mar; 171(3):1319-23. PubMed ID: 14767341
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors in human endocrine tumors.
Reubi JC; Maurer R; von Werder K; Torhorst J; Klijn JG; Lamberts SW
Cancer Res; 1987 Jan; 47(2):551-8. PubMed ID: 3024822
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]